Your numbers are a little off. The NEJM article was published a few hours ago: https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

RAS G12 population mOS: daraxonrasib 13.2 months / chemotherapy 6.6 months Overall population mOS: daraxonrasib 13.2 months / chemotherapy 6.7 months

RAS G12 population mPFS: daraxonrasib 7.3 months / chemotherapy 3.5 months Overall population PFS: daraxonrasib 7.2 months / chemotherapy 3.6 months

> Thus the treatment had provided them a median life extension of about 3/4 years. The lucky ones probably have got more than an extra year.

The 'median' patient in this trial lived ~6.6m longer if they received daraxonrasib. It's worth noting that the performance of the chemotherapy arms was stronger in this trial than previous trials of second-line chemotherapy; whether this reflects better care or a prognostically-superior trial population remains to be seen.